Valuation: Relay Therapeutics, Inc.

Market Cap 4.02B 3.6B 3.32B 3B 5.62B 382B 5.72B 39.46B 15.86B 201B 15.09B 14.77B 633B P/E 2026 *
-11.4x
P/E 2027 * -11.4x
Enterprise Value 3.45B 3.09B 2.85B 2.58B 4.82B 328B 4.91B 33.86B 13.61B 172B 12.95B 12.67B 544B EV / Sales 2026 *
308x
EV / Sales 2027 * 200x
Free-Float
91.42%
Yield 2026 *
-
Yield 2027 * -
1 day-5.75%
1 week+0.94%
Current month+1.66%
1 month+1.66%
3 months-5.66%
6 months+41.59%
Current year+116.90%
1 week 17.82
Extreme 17.82
20.2
1 month 16.13
Extreme 16.13
20.2
Current year 7.01
Extreme 7.01
21.27
1 year 5.95
Extreme 5.95
21.27
3 years 1.78
Extreme 1.775
21.27
5 years 1.78
Extreme 1.775
37.52
10 years 1.78
Extreme 1.775
64.37
Manager TitleAgeSince
Chief Executive Officer 52 01/03/2017
Director of Finance/CFO 49 01/04/2018
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 54 04/05/2015
Director/Board Member 66 01/07/2016
Director/Board Member 52 01/03/2017
Date Insider Type Main position Quantity % Market Cap. Importance
7/10/26 Sell

Chief Executive Officer

-48,199 0.0220%
6/10/26 Sell

Chief Financial Officer

-17,717 0.0081%
8/9/26 Sell

Chief Financial Officer

-17,717 0.0081%
Change 5-day change 1-year change 3-year change Capi.($)
-5.75%+0.94%+150.00%+194.54% 4.02B
-0.62%-1.87%+46.31%+56.99% 63.77B
+0.35%+3.20%+14.92%+84.55% 56.37B
+0.53%+1.96%+15.37%+106.81% 54.62B
-2.81%-4.31%+23.50%+50.90% 44.06B
-0.33%-1.93%+20.15%+98.45% 42.11B
+0.55%+2.31%+224.97%+942.56% 41B
+3.27%+47.96%+112.67%+96.48% 34.92B
+1.22%-1.44%+14.89%+47.15% 32.82B
+0.89%+20.55%-42.03%+373.03% 24.7B
Average -0.27%+6.88%+58.07%+205.14% 39.84B
Weighted average by Cap. +0.12%+5.40%+49.53%+186.21%

Financials

2026 *2027 *
Net sales 11.19M 10.03M 9.23M 8.35M 15.63M 1.06B 15.91M 110M 44.11M 558M 41.97M 41.08M 1.76B 17.91M 16.06M 14.78M 13.38M 25.03M 1.7B 25.48M 176M 70.64M 894M 67.22M 65.79M 2.82B
Net income -320M -287M -264M -239M -447M -30.4B -455M -3.14B -1.26B -15.98B -1.2B -1.18B -50.42B -347M -311M -287M -259M -485M -32.98B -494M -3.41B -1.37B -17.34B -1.3B -1.28B -54.71B
Net Debt -571M -512M -471M -426M -797M -54.19B -812M -5.6B -2.25B -28.5B -2.14B -2.1B -89.9B -442M -396M -365M -330M -618M -41.97B -629M -4.34B -1.74B -22.07B -1.66B -1.62B -69.62B
Projected Income Statement - Annual - Relay Therapeutics, Inc.
Logo Relay Therapeutics, Inc.
Relay Therapeutics, Inc. is a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. The Company's Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company's lead clinical asset, zovegalisib (RLY-2608), is the pan-mutant selective PI3Ka inhibitor to enter clinical development and is currently in a Phase 3 clinical trial (ReDiscover-2) in HR+/HER2- metastatic breast cancer. Zovegalisib is also being investigated in a group of genetic disease indications called PI3Ka-driven vascular anomalies. Its pipeline also includes programs for NRAS-driven solid tumors and Fabry disease.
Employees
202
Date Price Change Volume
30/10/26 USD 18.35 -5.75% 3,596,210
29/10/26 USD 19.47 -1.12% 1,945,348
28/10/26 USD 19.69 +4.51% 2,808,741
27/10/26 USD 18.84 +3.97% 2,258,311
26/10/26 USD 18.12 -0.33% 1,585,748
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Relay Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
18.35USD
Average target price
27.58USD
Spread / Average Target
+50.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Relay Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. RLAY Stock